

**REMARKS**

In this amendment and response, new claims 65-80 have been added to more completely describe applicants' invention. Claims 33, 40-50, and 57-64 have been canceled without prejudice or disclaimer. The new claims are fully supported by the specification, including the claims of the application as originally filed. No new matter has been introduced by virtue of the new claims. Currently pending are claims 1-32, 34-39, 51-56, and 65-80.

In the Restriction Requirement, the Examiner has grouped claims 1-12 and 14-64 into twelve (12) distinct inventions. To provide a complete response, the applicant elects, with traverse, the claims of Group VII drawn to a method for inhibiting or killing myeloma tumor cells or ovarian cancer tumor cells in a patient with an antibody cytotoxic conjugate.

However, it is respectfully submitted that the Group VII claims directed to a method for inhibiting or killing myeloma tumor cells or ovarian cancer tumor cells in a patient with an antibody cytotoxic conjugate, i.e., claims 19-20, should be examined in conjunction with the Group VI claims directed to a method for inhibiting or killing myeloma tumor cells or ovarian cancer tumor cells in a patient, i.e., claim 18 and Group IX claims directed to a method for inhibiting or killing myeloma cells in an isolated cellular sample, i.e., claim 25-29. Indeed, the subject matter claimed in the three Groups relate to the activity of the antibody as used in the methods for inhibiting or killing tumor cells or ovarian cancer tumor cells. Moreover, a number of the searchable terms are common between the method claims.

Given the relationship between the claims in Group VII, Group VI, and Group IX it is believed that there is no undue or serious burden placed on the Examiner in either the search for relevant art in the U.S. Patent shoes and the scientific literature, or in the examination of the claims of Groups VII, VI and IX. Thus, the claims of Group VII, VI and IX should be searched and examined on the merits together. Accordingly, it is respectfully requested that the claims of Groups VII, VI and IX be regrouped and searched and examined together in view of the art.

The above described election of the Group VII claims has been made to provide a complete response to the restriction requirement in the subject application. The applicant preserves the right to timely file one or more divisional applications on the subject matter of any and all non-elected Groups as set forth in the June 25, 2003 Patent Office Communication.



Docket No.: 3828-4000US1


**AUTHORIZATION**

Should any additional fee(s) be required by the filing of this response, the Assistant Commissioner is hereby authorized herein to charge the amount of any fee(s) that is/are properly assessable in this application to Deposit Account No. 13-4500, Docket No.: 3828-4000US1. **A duplicate copy of this sheet is attached.**

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: July 25, 2003

By:   
Paula K. Wittmayer  
Registration No.: 53,785

Correspondence Address:  
Morgan & Finnegan, L.L.P.  
345 Park Avenue  
New York, New York 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile